london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

A single-centre study of ocriplasmin in a homogenous group of patients with vitreomacular traction

Poster Details

First Author: P.Szurman GERMANY

Co Author(s):    S. Kazerounian   M. Waizel   K.T. Boden            0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

Ocriplasmin (JETREA®; Alcon) has been available in Germany for the treatment of patients with vitreomacular traction (VMT), including when associated with a macular hole ≤400 µm, since May 2013. This study was designed to evaluate ocriplasmin treatment in a homogenous group of patients with VMT, classified according to the International Vitreomacular Traction Study (IVTS) Group criteria.

Setting:

Patients with optical coherence tomography (OCT)-confirmed VMT, who were treated with ocriplasmin between July 2013 and January 2014 (inclusive), at the Knappschaft Eye Clinic, Sulzbach, Germany.

Methods:

A total of 24 eyes of 23 patients with visually significant VMT were treated with a single intravitreal injection of ocriplasmin 125 µg. Diagnosis was made with spectral domain OCT (SD-OCT). The patients were assigned to subgroups with either focal or broad vitreomacular adhesion (VMA), according to the IVTS Group classification. The primary study endpoint was posterior vitreomacular detachment 4 weeks after injection; secondary endpoints were best-corrected visual acuity (BCVA), macular thickness and morphology after injection.

Results:

There were 23 patients (24 eyes) who completed the 1-month follow-up visit. At this timepoint, 10 out of 24 eyes showed a resolution of the VMT on SD-OCT (success rate 41.7%). Successfully treated eyes showed a mean reduction in macular thickness from 372 µm to 360 µm (p=0.19). The same eyes showed a mean (±standard deviation) BCVA improvement from logMAR 0.25 (±0.60) to logMAR 0.21 (±0.62) 1 month after injection. Subgroup analysis showed no significant difference between eyes with broad or focal VMA.

Conclusions:

This is the first study to evaluate intravitreal ocriplasmin treatment in a homogenous group of patients with VMT alone. Our results show that ocriplasmin treatment resolves VMT in 41.7% of eyes. In these eyes, a slight improvement in visual acuity was observed 1 month after injection. Subgroup analysis showed no difference in the type of adhesion as classified by the IVTS Group.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy